CLCN2

Across TCGA pan-cancer cohorts, CLCN2 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of CLCN2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CLCN2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CLCN2 is over-expressed in tumor, although a few such as COAD and THCA show the opposite, repressed pattern.

HNSC, BLCA, and COAD are the cancer types where CLCN2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLCN2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+1.578	<.001	12	view →
BLCA	Female	All	+1.302	<.001	12	view →
COAD	Female	II,III,IV	−1.363	<.001	11	view →
LIHC	Female	II,III,IV	+1.308	<.001	9	view →
LUAD	Female	III,IV	+1.080	<.001	9	view →
STAD	Male	II,III,IV	+1.472	<.001	8	view →
LUSC	Female	All	+1.900	<.001	7	view →
KIRP	All	IV	+1.014	.001	7	view →
THCA	All	All	−0.215	.003	7	view →
UCEC	All	II,III,IV	+1.364	<.001	6	view →
BRCA	All	III,IV	+0.846	<.001	6	view →
CHOL	Male	All	+3.053	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

CLCN2–HNSC

Open the HNSC breakdown →